Literature DB >> 18228003

Elucidation of susceptible factors to endoplasmic reticulum stress-mediated anticancer activity in human hepatocellular carcinoma.

Po-Cheng Chiang1, Jui-Ling Hsu, Ting-Chun Yeh, Shiow-Lin Pan, Jih-Hwa Guh.   

Abstract

The initiation of endoplasmic reticulum (ER) stress has been suggested to play potential roles in hepatocarcinogenesis. However, many obstacles remain as to whether ER stress plays a role in carcinogenesis or tumoricide. This study sought to identify the signals that can serve as anticancer effectors in cells in response to ER stress. Tunicamycin (an N-glycosylation inhibitor) inhibited cell proliferation with IC(50) values of 0.19 and 0.62 microg/ml in hepatoma (Hep) 3B and HepG2 cells, respectively. It induced G1 arrest of the cell cycle in both cell lines. The anticancer mechanism of tunicamycin was investigated in Hep3B cells. Tunicamycin induced a rapid decline of cyclin D1 and cyclin A expression and an early increase of glucose-related protein (GRP) 78 and growth arrest and DNA damage-inducible transcription factor (GADD) 153 levels. Cyclin A was the most sensitive regulator to tunicamycin-triggered degradation mechanism. The association of p27(Kip1) with cyclin D1/cyclin-dependent kinase (Cdk) 4 was also increased by tunicamycin. The inhibition of GADD153 expression by transfection of GADD153 antisense did not modify tunicamycin-induced G1 arrest and cyclin/Cdk expressions. The knockdown of GRP78 expression by the siRNA transfection technique moderately increased tunicamycin-induced apoptosis but not the antiproliferative effect by sulforhodamine B assay. We suggest that tunicamycin induces G1 arrest through down-regulation of cyclins and Cdks, in which cyclin A is more susceptible to ER stress-triggered degradation mechanism in Hep3B cells. The increased association of p27(Kip1) with cyclin D1/Cdk4 may also contribute to tunicamycin-induced cell-cycle arrest. GADD153 and GRP78 play a minor role in tunicamycin-mediated antiproliferative effect, although GRP78 moderately inhibits apoptosis in Hep3B cells. These data provide evidence that cell-cycle regulators are susceptible factors in hepatocellular carcinoma (HCC) responsive to ER stress.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228003     DOI: 10.1007/s00210-007-0249-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

1.  Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins.

Authors:  L Kanter-Lewensohn; A Dricu; L Girnita; J Wejde; O Larsson
Journal:  Growth Factors       Date:  2000       Impact factor: 2.511

Review 2.  The unfolded protein response: an intracellular signalling pathway with many surprising features.

Authors:  C Sidrauski; R Chapman; P Walter
Journal:  Trends Cell Biol       Date:  1998-06       Impact factor: 20.808

3.  (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78.

Authors:  Svetlana P Ermakova; Bong Seok Kang; Bu Young Choi; Hong Seok Choi; Todd F Schuster; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.

Authors:  Ramachandra K Reddy; Changhui Mao; Peter Baumeister; Richard C Austin; Randal J Kaufman; Amy S Lee
Journal:  J Biol Chem       Date:  2003-03-28       Impact factor: 5.157

5.  Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis.

Authors:  Masahiro Shuda; Nobuo Kondoh; Nobuo Imazeki; Kenji Tanaka; Tetsuya Okada; Kazutoshi Mori; Akiyuki Hada; Masaaki Arai; Toru Wakatsuki; Osamu Matsubara; Naoki Yamamoto; Mikio Yamamoto
Journal:  J Hepatol       Date:  2003-05       Impact factor: 25.083

6.  Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction.

Authors:  H Wajant; F J Johannes; E Haas; K Siemienski; R Schwenzer; G Schubert; T Weiss; M Grell; P Scheurich
Journal:  Curr Biol       Date:  1998-01-15       Impact factor: 10.834

7.  Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line.

Authors:  A Cavazzoni; M Galetti; C Fumarola; R R Alfieri; L Roz; F Andriani; P Carbognani; M Rusca; G Sozzi; P G Petronini
Journal:  Cancer Lett       Date:  2006-04-17       Impact factor: 8.679

8.  Cell cycle-related signaling pathways modulated by peripheral benzodiazepine receptor ligands in colorectal cancer cells.

Authors:  Kerstin Maaser; Andreas P Sutter; Antje Krahn; Michael Höpfner; Patricia Grabowski; Hans Scherübl
Journal:  Biochem Biophys Res Commun       Date:  2004-11-12       Impact factor: 3.575

9.  CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest.

Authors:  M V Barone; A Crozat; A Tabaee; L Philipson; D Ron
Journal:  Genes Dev       Date:  1994-02-15       Impact factor: 11.361

10.  Endoplasmic reticulum stress triggers an acute proteasome-dependent degradation of ATF6.

Authors:  Min Hong; Mingqing Li; Changhui Mao; Amy S Lee
Journal:  J Cell Biochem       Date:  2004-07-01       Impact factor: 4.429

View more
  2 in total

Review 1.  Endoplasmic reticulum stress in liver disease.

Authors:  Harmeet Malhi; Randal J Kaufman
Journal:  J Hepatol       Date:  2010-11-13       Impact factor: 25.083

2.  New castanospermine glycoside analogues inhibit breast cancer cell proliferation and induce apoptosis without affecting normal cells.

Authors:  Ghada Allan; Halima Ouadid-Ahidouch; Elena M Sanchez-Fernandez; Rocío Risquez-Cuadro; José M Garcia Fernandez; Carmen Ortiz-Mellet; Ahmed Ahidouch
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.